Eribulin Improves Overall Survival in Advanced Soft-tissue Sarcoma

Share this content:
Eribulin improved overall survival compared with dacarbazine in patients with advanced soft-tissue sarcoma.
Eribulin improved overall survival compared with dacarbazine in patients with advanced soft-tissue sarcoma.

Eribulin improved overall survival compared with dacarbazine in patients with advanced soft-tissue sarcoma, a study published in the journal The Lancet Oncology has shown.1

Because a non-randomized, phase 2 trial demonstrated activity and tolerability of eribulin in advanced or metastatic soft-tissue sarcoma, researchers sought to compare overall survival in patients who received eribulin with that in patients who received dacarbazine in a phase 3 study.

For the international, open-label study, researchers enrolled 452 patients 18 years or older with intermediate-grate or high-grade advanced liposarcoma or leiomyosarcoma who had received at least 2 prior systemic therapies, including an anthracycline, for advanced disease.

Participants were randomly assigned 1:1 to receive eribulin mesylate 1.4 mg/m2 intravenously on days 1 and 8, or dacarbazine 850 - 1200 mg/m2 intravenously on day 1, every 21 days until disease progression.

Results showed that median overall survival was 13.5 months (95% CI, 10.9 - 15.6) with eribulin vs 11.5 months (95% CI, 9.6 - 13.0) with dacarbazine (HR, 0.77; 95% CI, 0.62 - 0.95; P = .0169).

RELATED: FDA Approves Eribulin for Unresectable, Metastatic Liposarcoma

In regard to safety, treatment-related adverse events occurred in 99% of patients who received eribulin compared with 97% of those who received dacarbazine. Grade 3 or higher adverse events were more frequently reported in the eribulin group than the dacarbazine group, and 1 death in the eribulin arm was considered treatment-related.

In January 2016, the U.S. Food and Drug Administration approved eribulin for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

Reference

  1. Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial [published online ahead of print February 10, 20016]. Lancet. doi: 10.1016/S0140-6736(15)01283-0.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs